PUBLIC COMPANY
save$FATEFATE THERAPEUTICS INC
$FATESan Diego, CA, USupdated 12d ago
community read0 votes
pipeline
8
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(8)
pipeline depth8 products
3Preclinical5Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- phase1FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- phase1FT819 in Subjects With B-cell Malignancies
- phase1A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- phase1FT576 in Subjects With Multiple Myeloma
- phase1FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- phase1FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
- phase1FT516 in Subjects With Advanced Hematologic Malignancies
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 20, 26otherRedmile Group, LLC · 8,977,624 sh
- Apr 20, 26otherRedmile Group, LLC · 8,977,624 sh
- Apr 20, 26otherRedmile Group, LLC · 3,691,324 sh
- Apr 20, 26otherRedmile Group, LLC · 3,691,324 sh
- Apr 20, 26otherRedmile Group, LLC · 266,280 sh
- Apr 20, 26otherRedmile Group, LLC · 266,280 sh
🐶 Hiring Signal
News
- Key Senate panel backs Trump’s picks for CDC, pandemic preparednessIn win for RFK Jr., Senate committee sends nominations of Erica Schwartz for CDC director and Sean Kaufman for ASPR to full Senate.stat · 12d ago
- FDA reminds investors about the risks of advisory panelsTwo days, two similar briefing documents and two companies with diving share prices. The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics andendpoints · 14d ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 15d ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 15d ago
- FDA panel confronting peptide controversyToday's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."stat · 19d ago
- STAT+: At key hearing, Kennedy’s ouster of former CDC director looms over nominee to replace herErica Schwartz and Sean Kaufman navigated tough questions about vaccines, political independence, and pushing back on RFK Jr.stat · 27d ago
- Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorPlus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary end…endpoints · 1mo ago
- Tiny HHS office tasked with protecting research participants’ safety is running on fumesOHRP has experienced an unprecedented exodus of ethics expertise, raising concerns about its ability to effectively protect volunteers.stat · 2mo ago
- STAT+: Bill Cassidy risked his legacy. It may not be enough to save his careerSen. Bill Cassidy risked his legacy. It may not be enough to save his career.stat · 3mo ago
- Supreme Court extends mifepristone deadlineThe deadliest drug in the country, the new name for PCOS, and more health news from Morning Roundsstat · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that